The combined sales of five drugs developed by Massachusetts-based biotech firms that were approved this year could reach more than $14 billion in 2018. Among these drugs, Gilead Sciences' hepatitis C drug Sovaldi is forecast to gain the highest revenue in five years with expected sales of $6 billion, followed by Biogen Idec's multiple sclerosis drug Tecfidera, which is predicted to generate $4.2 billion in revenue.

Related Summaries